Vasodilators currently prescribed in the treatment of congestive heart failure represent a wide class of drugs. In acute heart failure, the therapeutic choice should be based on considerations about the mechanisms of drug action as well as the site of action on the vascular bed, together with the patient's hemodynamic and clinical characteristics. For medium-to long-term treatment the choice should be oriented towards drugs which do not activate compensatory or feedback regulation mechanisms. Use of therapeutic agents such as inhibitors of the angiotensin converting enzyme will avoid the development of physiological tolerance
Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the t...
Chapter 1 offers an introduction in which the place of vasodilator therapy in heart failure is descr...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...
The current status of the use of vasodilator drugs in the treatment of acute and chronic heart failu...
The value of vasodilator therapy in acute and chronic heart failure is well established. Vasodilator...
Oral vasodilators have proved to be valuable drugs in the management of systolic or diastolic conges...
Although substantial progress has been made in the last 5 years in the development of vasodilator an...
Heart failure (HF) and coronary insufficiency are common amongst surgical and critical care patients...
AbstractVasodilator drugs have been undergoing evaluation as therapy for heart failure for > 20 year...
AbstractCongestive heart failure is a common clinieal syndrome, with a relatively poor prognosis in ...
Agents with vasodilator properties (AVDs) are frequently used in the treatment of acute heart failur...
Although we have recently witnessed substantial progress in management and outcome of patients with ...
Although we have recently witnessed substantial progress in management and outcome of patients with ...
International audienceHeart failure is the most common cardiovascular reason for hospital admission ...
Acute Heart Failure Syndromes are defined as the rapid progression, or de novo presentation, of hear...
Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the t...
Chapter 1 offers an introduction in which the place of vasodilator therapy in heart failure is descr...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...
The current status of the use of vasodilator drugs in the treatment of acute and chronic heart failu...
The value of vasodilator therapy in acute and chronic heart failure is well established. Vasodilator...
Oral vasodilators have proved to be valuable drugs in the management of systolic or diastolic conges...
Although substantial progress has been made in the last 5 years in the development of vasodilator an...
Heart failure (HF) and coronary insufficiency are common amongst surgical and critical care patients...
AbstractVasodilator drugs have been undergoing evaluation as therapy for heart failure for > 20 year...
AbstractCongestive heart failure is a common clinieal syndrome, with a relatively poor prognosis in ...
Agents with vasodilator properties (AVDs) are frequently used in the treatment of acute heart failur...
Although we have recently witnessed substantial progress in management and outcome of patients with ...
Although we have recently witnessed substantial progress in management and outcome of patients with ...
International audienceHeart failure is the most common cardiovascular reason for hospital admission ...
Acute Heart Failure Syndromes are defined as the rapid progression, or de novo presentation, of hear...
Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the t...
Chapter 1 offers an introduction in which the place of vasodilator therapy in heart failure is descr...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...